A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease

Journal of Neural Transmission

Volumn 121, Issue 8, 2014, Pages 849-859

  Ambrosi, Giulia ^a,b   Cerri, Silvia ^a   Blandini, Fabio ^a  

^a C MONDINO NATIONAL NEUROLOGICAL INSTITUTE   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

Calcium; Excitotoxicity; Glutamate receptors; Metabolic shift; NMDARs and mGluR5 antagonists

Indexed keywords

CALCIUM; GLUTAMATE RECEPTOR; GLUTAMIC ACID; IONOTROPIC RECEPTOR; LEVODOPA; METABOTROPIC RECEPTOR;

ARTICLE; ASTROCYTE; CELL INTERACTION; EXCITOTOXICITY; GLUCOSE METABOLISM; HUMAN; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SYNAPSE; UNSPECIFIED SIDE EFFECT; ANIMAL; CELL DEATH; METABOLISM; NERVE CELL; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CELL DEATH; GLUTAMIC ACID; HUMANS; NEURONS; PARKINSON DISEASE; SYNAPSES;

EID: 84906868160     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-013-1149-z     Document Type: Article

References (103)

1. Addy C, Assaid C, Hreniuk D et al (2009) Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease. J Clin Pharmacol 49:856-864. doi:10.1177/0091270009336735
2. Alagarsamy S, Marino MJ, Rouse ST et al (1999) Activation of NMDA receptors reverses desensitization of mGluR5 in native and recombinant systems. Nat Neurosci 2:234-240. doi:10.1038/6338
3. Albin RL, Greenamyre JT (1992) Alternative excitotoxic hypotheses. Neurology 42:733-738
4. Al-Sweidi S, Morissette M, Di Paolo T (2012) Effect of oestrogen receptors on brain NMDA receptors of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. J Neuroendocrinol 24:1375-1385. doi:10.1111/j.1365-2826.2012.02349.x
5. Amalric M, Lopez S, Goudet C et al (2013) Group III and subtype 4 metabotropic glutamate receptor agonists: discovery and pathophysiological applications in Parkinson's disease. Neuropharmacology 66:53-64. doi:10.1016/j.neuropharm.2012.05.026
6. Ambrosi G, Armentero M-T, Levandis G et al (2010) Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease. Brain Res Bull 82:29-38. doi:10.1016/j.brainresbull.2010.01.011
7. Armentero M-T, Fancellu R, Nappi G et al (2006) Prolonged blockade of NMDA or mGluR5 glutamate receptors reduces nigrostriatal degeneration while inducing selective metabolic changes in the basal ganglia circuitry in a rodent model of Parkinson's disease. Neurobiol Dis 22:1-9. doi:10.1016/j.nbd. 2005.09.010
8. Bak LK, Schousboe A, Sonnewald U, Waagepetersen HS (2006) Glucose is necessary to maintain neurotransmitter homeostasis during synaptic activity in cultured glutamatergic neurons. J Cereb Blood Flow Metab 26:1285-1297. doi:10.1038/sj. jcbfm.9600281
9. Barger SW, Goodwin ME, Porter MM, Beggs ML (2007) Glutamate release from activated microglia requires the oxidative burst and lipid peroxidation. J Neurochem 101:1205-1213. doi:10.1111/j.1471-4159.2007.04487.x
10. Battaglia G, Busceti CL, Pontarelli F et al (2003) Protective role of group-II metabotropic glutamate receptors against nigro-striatal degeneration induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. Neuropharmacology 45:155-166
11. Battaglia G, Busceti CL, Molinaro G et al (2004) Endogenous activation of mGlu5 metabotropic glutamate receptors contributes to the development of nigro-striatal damage induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice. J Neurosci 24:828-835. doi:10.1523/JNEUROSCI.3831-03.2004
12. Battaglia G, Busceti CL, Molinaro G et al (2006) Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J Neurosci 26:7222-7229. doi:10.1523/JNEUROSCI.1595-06.2006
13. Berg D, Godau J, Trenkwalder C et al (2011) AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials. Mov Disord 26:1243-1250. doi:10.1002/mds. 23616
14. Blandini F, Nappi G, Greenamyre JT (2001) Subthalamic infusion of an NMDA antagonist prevents basal ganglia metabolic changes and nigral degeneration in a rodent model of Parkinson's disease. Ann Neurol 49:525-529
15. Breysse N, Baunez C, Spooren W et al (2002) Chronic but not acute treatment with a metabotropic glutamate 5 receptor antagonist reverses the akinetic deficits in a rat model of parkinsonism. J Neurosci 22:5669-5678
16. Bruno V, Battaglia G, Copani A et al (2001) Metabotropic glutamate receptor subtypes as targets for neuroprotective drugs. J Cereb Blood Flow Metab 21:1013-1033. doi:10.1097/00004647-200109000-00001
17. Chan H, Paur H, Vernon AC et al (2010) Neuroprotection and functional recovery associated with decreased microglial activation following selective activation of mGluR2/3 receptors in a rodent model of Parkinson's disease. Parkinsons Dis. doi:10. 4061/2010/190450
18. Chang PK-Y, Verbich D, McKinney RA (2012) AMPA receptors as drug targets in neurological disease-advantages, caveats, and future outlook. Eur J Neurosci 35:1908-1916. doi:10.1111/j.1460-9568.2012.08165.x
19. Clarke CE, Cooper JA, Holdich TAA (2001) Randomized, doubleblind, placebo-controlled, ascending-dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations. Clin Neuropharmacol 24:133-138
20. Coccurello R, Breysse N, Amalric M (2004) Simultaneous blockade of adenosine A2A and metabotropic glutamate mGlu5 receptors increase their efficacy in reversing Parkinsonian deficits in rats. Neuropsychopharmacology 29:1451-1461. doi:10.1038/sj.npp.1300444
21. Dall'Olio R, Rimondini R, Gandolfi O (1995) The competitive NMDA antagonists CGP 43487 and APV potentiate dopaminergic function. Psychopharmacology 118:310-315
22. DeCarvalho LP, Bochet P, Rossier J (1996) The endogenous agonist quinolinic acid and the non endogenous homoquinolinic acid discriminate between NMDAR2 receptor subunits. Neurochem Int 28:445-452
23. DeLau LML, Breteler MMB (2006) Epidemiology of Parkinson's disease. Lancet neurol 5:525-535. doi:10.1016/S1474-4422(06) 70471-9
24. Di Michele F, Luchetti S, Bernardi G et al (2013) Neurosteroid and neurotransmitter alterations in Parkinson's disease. Front Neuroendocrinol 34:132-142. doi:10.1016/j.yfrne.2013.03.001
25. Dunah AW, Wang Y, Yasuda RP et al (2000) Alterations in subunit expression, composition, and phosphorylation of striatal Nmethyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol Pharmacol 57:342-352
26. Duty S (2010) Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease. Br J Pharmacol 161:271-287. doi:10.1111/j.1476-5381. 2010.00882.x
27. Duty S (2012) Targeting glutamate receptors to tackle the pathogenesis, clinical symptoms and levodopa-induced dyskinesia associated with Parkinson's disease. CNS drugs 26:1017-1032. doi:10.1007/s40263-012-0016-z
28. Eggert K, Squillacote D, Barone P et al (2010) Safety and efficacy of perampanel in advanced Parkinson's disease: a randomized, placebo-controlled study. Mov Disord 25:896-905. doi:10.1002/mds.22974
29. Elahi B, Phielipp N, Chen R (2012) N-Methyl-D-Aspartate antagonists in levodopa induced dyskinesia: a meta-analysis. Can J Neurol 39:465-472
30. Ferré S, Agnati LF, Ciruela F et al (2007) Neurotransmitter receptor heteromers and their integrative role in "local modules": the striatal spine module. Brain Res Rev 55:55-67. doi:10.1016/j. brainresrev.2007.01.007
31. Gao H-C, Zhu H, Song C-Y et al (2013) Metabolic changes detected by ex vivo high resolution 1H NMR spectroscopy in the striatum of 6-OHDA-induced Parkinson's rat. Mol Neurobiol 47:123-130. doi:10.1007/s12035-012-8336-z
32. Gardoni F, Zianni E, Eramo A et al (2011) Effect of rasagiline on the molecular composition of the excitatory postsynaptic density. Eur J Pharmacol 670:458-463. doi:10.1016/j.ejphar.2011.09.028
33. Gasparini F, Di Paolo T, Gomez-Mancilla B (2013) Metabotropic glutamate receptors for Parkinson's disease therapy. Parkinsons Dis 2013:196028. doi:10.1155/2013/196028
34. Greco B, Lopez S, van der Putten H et al (2010) Metabotropic glutamate 7 receptor subtype modulates motor symptoms in rodent models of Parkinson's disease. J Pharmacol Exp Ther 332:1064-1071. doi:10.1124/jpet.109.162115
35. Hardingham GE, Bading H (2003) The Yin and Yang of NMDA receptor signalling. Trends Neurosci 26:81-89. doi:10.1016/S0166-2236(02)00040-1
36. Hardingham GE, Bading H (2010) Synaptic versus extrasynaptic NMDA receptor signalling: implications for neurodegenerative disorders. Nat Rev Neurosci 11:682-696. doi:10.1038/nrn2911
37. Hovelsø N, Sotty F, Montezinho LP et al (2012) Therapeutic potential of metabotropic glutamate receptor modulators. Curr Neuropharmacol 10:12-48. doi:10.2174/157015912799362805
38. Hsieh M-H, Ho S-C, Yeh K-Y et al (2012) Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model. Pharmacol Biochem Behav 102:64-71. doi:10.1016/j.pbb.2012.03.022
39. Huang CC, Lo SW, Hsu KS (2001) Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol 532:731-748
40. Huettner JE (2003) Kainate receptors and synaptic transmission. Prog Neurobiol 70:387-407
41. Hüls S, Högen T, Vassallo N et al (2011) AMPA-receptor-mediated excitatory synaptic transmission is enhanced by iron-induced α synuclein oligomers. J Neurochem 117:868-878. doi:10.1111/j.1471-4159.2011.07254.x
42. Johnson KA, Conn PJ, Niswender CM (2009) Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol Disord Drug Targets 8:475-491
43. Johnson KA, Jones CK, Tantawy MN et al (2013) The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease. Neuropharmacology 66:187-195. doi:10.1016/j.neuro pharm.2012.03.029
44. Kachroo A, Orlando LR, Grandy DK et al (2005) Interactions between metabotropic glutamate 5 and adenosine A2A receptors in normal and parkinsonian mice. J Neurosci 25:10414-10419. doi:10.1523/JNEUROSCI.3660-05.2005
45. Kaufman AM, Milnerwood AJ, Sepers MD et al (2012) Opposing roles of synaptic and extrasynaptic NMDA receptor signaling in cocultured striatal and cortical neurons. J Neurosci 32:3992-4003. doi:10.1523/JNEUROSCI.4129-11.2012
46. Kennedy MB (1997) The postsynaptic density at glutamatergic synapses. Trends Neurosci 20:264-268
47. Koutsilieri E, Riederer P (2007) Excitotoxicity and new antiglutamatergic strategies in Parkinson's disease and Alzheimer's disease. Parkinsonism Relat Disord 13(Suppl 3):S329-S331. doi:10.1016/S1353-8020(08)70025-7
48. LePoul E, Boléa C, Girard F et al (2012) A potent and selective metabotropic glutamate receptor 4 positive allosteric modulator improves movement in rodent models of Parkinson's disease. J Pharmacol Exp Ther 343:167-177. doi:10.1124/jpet.112.196063
49. Lee M (2013) Neurotransmitters and microglial-mediated neuroinflammation. Curr Protein Pept Sci 14:21-32
50. Lee DY, Lee K-S, Lee HJ et al (2008) Kynurenic acid attenuates MPP(?)-induced dopaminergic neuronal cell death via a Baxmediated mitochondrial pathway. Eur J Cell Biol 87:389-397. doi:10.1016/j.ejcb.2008.03.003
51. Lees A, Fahn S, Eggert KM et al (2012) Perampanel, an AMPA antagonist, found to have no benefit in reducing "off" time in Parkinson's disease. Mov Disord 27:284-288. doi:10.1002/mds.23983
52. Levandis G, Bazzini E, Armentero M-T et al (2008) Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease. Neurobiol Dis 29:161-168. doi:10.1016/j.nbd.2007.08.011
53. Lipton SA (2007) Pathologically activated therapeutics for neuroprotection. Nat Rev Neurosci 8:803-808. doi:10.1038/nrn2229
54. Liu S, Zhao M (2013) Neuroprotective effect of estrogen: role of nonsynaptic NR2B-containing NMDA receptors. Brain Res Bull 93:27-31. doi:10.1016/j.brainresbull.2012.10.004
55. Lundblad M, Decressac M, Mattsson B, Björklund A (2012) Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proc Natl Acad Sci USA 109:3213-3219. doi:10.1073/pnas.1200575109
56. Marques O, Outeiro TF (2012) Alpha-synuclein: from secretion to dysfunction and death. Cell Death Dis 3:e350. doi:10.1038/cddis.2012.94
57. McNaught KS, Jenner P (2000) Extracellular accumulation of nitric oxide, hydrogen peroxide, and glutamate in astrocytic cultures following glutathione depletion, complex I inhibition, and/or lipopolysaccharide-induced activation. Biochem Pharmacol 60:979-988
58. Mehta A, Prabhakar M, Kumar P et al (2013) Excitotoxicity: bridge to various triggers in neurodegenerative disorders. Eur J Pharmacol 698:6-18. doi:10.1016/j.ejphar.2012.10.032
59. Meissner WG, Frasier M, Gasser T et al (2011) Priorities in Parkinson's disease research. Nat Rev Drug Discov 10:377-393. doi:10.1038/nrd3430
60. Merino M, Vizuete ML, Cano J, Machado A (1999) The non-NMDA glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione and 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline, but not NMDA antagonists, block the intrastriatal neurotoxic effect of MPP?. J Neurochem 73:750-757
61. Misgeld U (2004) Innervation of the substantia nigra. Cell Tissue Res 318:107-114. doi:10.1007/s00441-004-0918-2
62. Morales I, Rodriguez M (2012) Self-induced accumulation of glutamate in striatal astrocytes and basal ganglia excitotoxicity. Glia 60:1481-1494. doi:10.1002/glia.22368
63. Moreau C, Delval A, Tiffreau V et al (2013) Memantine for axial signs in Parkinson's disease: a randomised, double-blind, placebo-controlled pilot study. J Neurol Neurosurg Psychiatry 84:552-555. doi:10.1136/jnnp-2012-303182
64. Morin N, Grégoire L, Gomez-Mancilla B et al (2010) Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 58:981-986. doi:10.1016/j.neuropharm.2009.12.024
65. Müller T, Kuhn W, Przuntek H (2005) Efficacy of budipine and placebo in untreated patients with Parkinson's disease. J Neural Transm 112:1015-1023. doi:10.1007/s00702-004-0247-3
66. Murray TK, Messenger MJ, Ward MA et al (2002) Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol Biochem Behav 73:455-466
67. Nguyen D, Alavi MV, Kim K-Y et al (2011) A new vicious cycle involving glutamate excitotoxicity, oxidative stress and mitochondrial dynamics. Cell Death Dis 2:e240. doi:10.1038/cddis.2011.117
68. Nicholls DG (2008) Oxidative stress and energy crises in neuronal dysfunction. Ann N Y Acad Sci 1147:53-60. doi:10.1196/annals.1427.002
69. Niswender CM, Conn PJ (2010) Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu Rev Pharmacol Toxicol 50:295-322. doi:10.1146/annurev.pharmtox.011008.145533
70. Noda M, BeppuK (2013) Possible contribution of microglial glutamate receptors to inflammatory response upon neurodegenerative diseases. J Neurol Dis 1:131. doi:10.4172/2329-6895.1000131
71. Nutt JG, Gunzler SA, Kirchhoff T et al (2008) Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Mov Disord 23:1860-1866. doi:10.1002/mds.22169
72. Ossowska K, Konieczny J, Wolfarth S, Pilc A (2005) MTEP, a new selective antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), produces antiparkinsonian-like effects in rats. Neuropharmacology 49:447-455. doi:10.1016/j.neuro pharm.2005.04.002
73. Paillé V, Picconi B, Bagetta V et al (2010) Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. J Neurosci 30:14182-14193. doi:10.1523/JNEUROSCI.2149-10.2010
74. Paoletti P, Bellone C, Zhou Q (2013) NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 14:383-400. doi:10.1038/nrn3504
75. Pellerin L, Magistretti PJ (1994) Glutamate uptake into astrocytes stimulates aerobic glycolysis: a mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci USA 91:10625-10629
76. Perez-Pinzon MA, Stetler RA, Fiskum G (2012) Novel mitochondrial targets for neuroprotection. J Cereb Blood Flow Metab 32:1362-1376. doi:10.1038/jcbfm.2012.32
77. Picconi B, Piccoli G, Calabresi P (2012) Synaptic dysfunction in Parkinson's disease. Adv Exp Med Biol 970:553-572. doi:10.1007/978-3-7091-0932-8_24
78. Price DL, Rockenstein E, Ubhi K et al (2010) Alterations in mGluR5 expression and signaling in Lewy body disease and in transgenic models of alpha-synucleinopathy-implications for excitotoxicity. PLoS One 5:e14020. doi:10.1371/journal.pone.0014020
79. Raju DV, Ahern TH, Shah DJ et al (2008) Differential synaptic plasticity of the corticostriatal and thalamostriatal systems in an MPTP-treated monkey model of parkinsonism. Eur J Neurosci 27:1647-1658. doi:10.1111/j.1460-9568.2008.06136.x
80. Rascol O, Barone P, Behari M et al (2012) Perampanel in Parkinson disease fluctuations: a double-blind randomized trial with placebo and entacapone. Clin Neuropharmacol 35:15-20. doi:10.1097/WNF.0b013e318241520b
81. Rebola N, Srikumar BN, Mulle C (2010) Activity-dependent synaptic plasticity of NMDA receptors. J Physiol 588:93-99. doi:10.1113/jphysiol.2009.179382
82. Rodriguez-Rodriguez P, Fernandez E, Almeida A, Bolaños JP (2012) Excitotoxic stimulus stabilizes PFKFB3 causing pentose-phosphate pathway to glycolysis switch and neurodegeneration. Cell Death Differ 19:1582-1589. doi:10.1038/cdd.2012.33
83. Rothstein JD, Dykes-Hoberg M, Pardo CA et al (1996) Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16:675-686
84. Salat D, Tolosa E (2013) Levodopa in the treatment of Parkinson's disease: current status and new developments. J Parkinsons Dis 3:255-269. doi:10.3233/JPD-130186
85. Salvatore MF, Davis RW, Arnold JC, Chotibut T (2012) Transient striatal GLT-1 blockade increases EAAC1 expression, glutamate reuptake, and decreases tyrosine hydroxylase phosphorylation at ser(19). Exp Neurol 234:428-436. doi:10.1016/j.expneurol.2012. 01.012
86. Santangelo RM, Acker TM, Zimmerman SS et al (2012) Novel NMDA receptor modulators: an update. Expert Opin Ther Pat 22:1337-1352. doi:10.1517/13543776.2012.728587
87. Sattler R, Charlton MP, Hafner M, Tymianski M (1998) Distinct influx pathways, not calcium load, determine neuronal vulnerability to calcium neurotoxicity. J Neurochem 71:2349-2364
88. Sawada H, Oeda T, Kuno S et al (2010) Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. PLoS One 5:e15298. doi:10.1371/journal.pone.0015298
89. Shoulson I, Penney J, McDermott M et al (2001) A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. Neurology 56:455-462
90. Silva-Adaya D, Pérez-De La Cruz V, Villeda-Herná'ndez J et al (2011) Protective effect of L-kynurenine and probenecid on 6-hydroxydopamine-induced striatal toxicity in rats: implications of modulating kynurenate as a protective strategy. Neurotoxicol Teratol 33:303-312. doi:10.1016/j.ntt.2010.10.002
91. Spieker S, Breit S, Klockgether T, Dichgans J (1999) Tremorlytic activity of budipine in Parkinson's disease. J Neural Transm Suppl 56:165-172
92. Stocchi F, Rascol O, Destee A et al (2013) AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. Mov Disord. doi:10.1002/mds.25561
93. Tavares RG, Tasca CI, Santos CES et al (2002) Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes. Neurochem Int 40:621-627
94. Turski L, Bressler K, Rettig KJ et al (1991) Protection of substantia nigra from MPP ? neurotoxicity by N-methyl-D-aspartate antagonists. Nature 349:414-418. doi:10.1038/349414a0
95. Varanese S, Howard J, Di Rocco A (2010) NMDA antagonist memantine improves levodopa-induced dyskinesias and "onoff" phenomena in Parkinson's disease. Mov Disord 25:508-510. doi:10.1002/mds.22917
96. Vidal E, Fukushima FB, Valle AP, Villas Boas PJF (2013) Unexpected improvement in levodopa-induced dyskinesia and on-off phenomena after introduction of memantine for treatment of Parkinson's disease dementia. J Am Geriatr Soc 61:170-172. doi:10.1111/jgs.12058
97. Wild AR, Akyol E, Brothwell SLC et al (2013) Memantine block depends on agonist presentation at the NMDA receptor in substantia nigra pars compacta dopamine neurones. Neuropharmacology 73C:138-146. doi:10.1016/j.neuropharm.2013. 05.013
98. Wolf E, Seppi K, Katzenschlager R et al (2010) Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord 25:1357-1363. doi:10.1002/mds.23034
99. Wu Y-N, Johnson SW (2009) Rotenone reduces Mg2?-dependent block of NMDA currents in substantia nigra dopamine neurons. Neurotoxicology 30:320-325. doi:10.1016/j.neuro.2009.01.002
100. Yin F, Sancheti H, Cadenas E (2012) Mitochondrial thiols in the regulation of cell death pathways. Antioxid Redox Signal 17:1714-1727. doi:10.1089/ars.2012.4639
101. Zá'dori D, Klivényi P, Plangá'r I et al (2011) Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. J Cell Mol Med 15:701-717. doi:10.1111/j.1582-4934.2010.01237.x
102. Zhang X-M, Zhu J (2011) Kainic Acid-induced neurotoxicity: targeting glial responses and glia-derived cytokines. Curr Neuropharmacol 9:388-398. doi:10.2174/157015911795596540
103. Zhou X, Hollern D, Liao J et al (2013) NMDA receptor-mediated excitotoxicity depends on the coactivation of synaptic and extrasynaptic receptors. Cell Death Dis 4:e560. doi:10.1038/cddis.2013.82